Johnson, R.L.; Laios, A.; Jackson, D.; Nugent, D.; Orsi, N.M.; Theophilou, G.; Thangavelu, A.; de Jong, D.
The Uncertain Benefit of Adjuvant Chemotherapy in Advanced Low-Grade Serous Ovarian Cancer and the Pivotal Role of Surgical Cytoreduction. J. Clin. Med. 2021, 10, 5927.
https://doi.org/10.3390/jcm10245927
AMA Style
Johnson RL, Laios A, Jackson D, Nugent D, Orsi NM, Theophilou G, Thangavelu A, de Jong D.
The Uncertain Benefit of Adjuvant Chemotherapy in Advanced Low-Grade Serous Ovarian Cancer and the Pivotal Role of Surgical Cytoreduction. Journal of Clinical Medicine. 2021; 10(24):5927.
https://doi.org/10.3390/jcm10245927
Chicago/Turabian Style
Johnson, Racheal Louise, Alexandros Laios, David Jackson, David Nugent, Nicolas Michel Orsi, Georgios Theophilou, Amudha Thangavelu, and Diederick de Jong.
2021. "The Uncertain Benefit of Adjuvant Chemotherapy in Advanced Low-Grade Serous Ovarian Cancer and the Pivotal Role of Surgical Cytoreduction" Journal of Clinical Medicine 10, no. 24: 5927.
https://doi.org/10.3390/jcm10245927
APA Style
Johnson, R. L., Laios, A., Jackson, D., Nugent, D., Orsi, N. M., Theophilou, G., Thangavelu, A., & de Jong, D.
(2021). The Uncertain Benefit of Adjuvant Chemotherapy in Advanced Low-Grade Serous Ovarian Cancer and the Pivotal Role of Surgical Cytoreduction. Journal of Clinical Medicine, 10(24), 5927.
https://doi.org/10.3390/jcm10245927